On October 8, 2024, PhRMA held a media briefing to address growing concerns over the Inflation Reduction Act (IRA) and its effects on the biopharmaceutical industry, Medicare Part D beneficiaries, and ...
To remain within the target range, the number of victims would have needed to decrease by 18% between 2022 and 2023, assuming a linear progression. Across Europe, a reduction of 1% has been achieved – ...